Speaker Profile

Ph.D., CTO, Burning Rock Dx
Biography

Dr. Zhang obtained PhD degree from Duke University in 2005. After completing his postdoctoral studies at the University of Washington and Howard Hughes Medical Institute in 2008, he then joined Illumina R&D as a assay development scientist in San Diego, and participating in multiple microarray and sequencing consumables development activities. As a team leader, he developed and launched dual-indexed Illumina library prep and sequencing products. He also led or contributed to the launch of multiple other TruSeq and Infinium products. In 2016, he joined BurningRock Dx, a leading Chinese start-up company focused on cancer diagnostics. As chief technology officer, he has led the company R&D team to implement next-generation sequencing technology in translational medicine and to further develop in vitro diagnostic products.

Session Abstract – PMWC 2019 Silicon Valley

Session Synopsis: Over the last few years, there has been extraordinary progress in Next-Generation Sequencing and with that we see genetic testing are now increasingly being used for the screening and diagnosis of both cancer and non-cancer conditions. This session will dive into specifics around cancer testing, where it is headed, applications, concerns, and opportunities.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!